Name: 7th Annual MarketsandMarkets Biomarker and Companion Diagnostics Conference
Start: 2022-06-16
End: 2022-06-17
Location: Double Tree by Hilton San Diego- Mission Valley

Leveraging next gen technologies beyond conventional biomarker drug discovery

The 7th Annual MarketsandMarkets Biomarker and Companion Diagnostics Conference scheduled to be held on 16th - 17th June 2022 in San Diego, CA would address the gaps between early stage biomarker development and the commercialization stage of biomarkers.

30+ experts from academia and industry will be presenting their current work in Biomarkers, Latest updates on regulatory guidelines and approvals, Cancer biomarker validation for clinical application, Biomarkers and Personalized Medicine, Impact of Big data in translational biomarker research and Future of Companion Diagnostics

Opportunity to develop long-lasting business relationships and networking opportunities with researchers, scientists, clinicians, academicians and professionals from Pharmaceutical companies, Bio-pharma companies, Universities, and Research institutes.

Over 20 presentations, round-tables, and panel discussions focused on the key opportunities and challenges in biomarker research, from precision medicine and companion diagnostics through to digital biomarkers and clinical trials.

Commercialization of CDx
Proteomics and Genomics based Biomarkers
Biomarker Drug Discovery and Assay Development
Multiplex Companion Diagnostics and Regulatory Guidelines
Design of clinical trials in CDx
Digital Biomarkers, Predictive Biomarkers, Precision Medicine and Big Data
Clinical Applications of Biomarkers in Immuno-Oncology, Neurology and Inflammatory Diseases

Researchers, scientists, clinicians, academicians and professionals from Pharmaceutical companies, Bio-pharma companies & Universities and Research institutes working in:

Biomarker discovery/development
Translational research
Clinical Biomarker
Biomarkers in IO and Neurological disorders
Imaging Biomarkers
Pathology
Companion Diagnostics
Biomarker Imaging
Proteomics Biomarkers
Experimental Medicine
Data Science
Biomarkers in Clinical Discovery
Immuno-oncology/Neuroscience Drug Discovery
Diagnostic Biomarkers development
Personalized Medicine
Immunology Biomarkers

CONFERENCE AGENDA

Registration	08:15 - 08:55
Opening Keynote from MarketsandMarkets	08:55 - 09:00
Opening Remarks from the Chairman Paul Kassner, Senior Vice President, Quantitative & Computational Biology , RAPT Therapeutics	09:00 - 09:05
Keynote Presentation: Implementing Biomarker Strategy in Late-Stage Clinical Trials Chetan Deshpande , Director, Biomarker Clinical Assay Lead in Global Product Development , Pfizer	09:05 - 09:40
Biomarkers in Clinical & Translational Development: Drug Discovery and Assay Development
Enhanced Biomarker Discovery and Validation Using TMT® Proteomics Ian Pike, Chief Scientific Officer, Proteome Sciences PLC	09:40 - 10:15
Multiplex IHC/IF_Applications in Clinical Trials and Diagnostics Buer Song, CEO , iCura Diagnostics	10:15 - 10:50
Morning Refreshments and Poster Presentation \| One-to-One Networking Meetings	10:50 - 11:35
Flow cytometry for development of clinical biomarkers and CDx Scott J. Bornheimer, Associate Director, Medical & Scientific Affairs, BD Biosciences	11:35 - 12:10
Blood and skin biomarkers from a first-in-human study of RPT193 - an oral CCR4 antagonist for the treatment of atopic dermatitis Paul Kassner, Senior Vice President, Quantitative & Computational Biology , RAPT Therapeutics	12:10 - 12:45
Novel approach for high sensitivity quantification of Antisense Oligonucleotides (ASOs) for pharmacokinetic (PK) characterization Shilpi Mahajan, Senior Scientist, Clinical Pharmacology and Quantitative Pharmacology, AstraZeneca	12:45 - 13:20
Lunch and Poster Presentation \| One-to-One Networking Meetings	13:20 - 14:20
Innovations in Biomarker Research: Digital Biomarkers, Precision Medicine and Big Data
Hypoxia biomarkers: Personalising cancer treatments by targeting hypoxia Joely Irlam , CEO , ManTRa Diagnostics	14:20 - 14:55
Artificial Intelligence, Explainability, and Transparency in Machine Learning Based Diagnostic Tests Robert Georgantas , Chief Scientific Officer , Biodesix	14:55 - 15:30
Bigger data = better data: Detect 7000 proteins at once with high throughput to optimize biomarker discovery Joe Gogain , Associate Director of Clinical Research and Development, Somalogic	15:30 - 16:05
Evening Refreshments and Poster Presentation \| One-to-One Networking Meetings	16:05 - 16:45
Biosignal Processing Units (BPUs): A Merger of Biology and Semiconductors Francie Barron, Vice President, Innovation Partnerships, Cardea Bio	16:45 - 17:20
Closing Remarks from the Chairman Paul Kassner, Senior Vice President, Quantitative & Computational Biology , RAPT Therapeutics	17:20 - 17:25
Drinks Reception & Networking	17:25 - 19:00

Registration	08:15 - 08:55
Welcome note from MarketsandMarkets	08:55 - 09:00
Opening Remarks from the Chairman Paul Kassner, Senior Vice President, Quantitative & Computational Biology , RAPT Therapeutics	09:00 - 09:05
Keynote Presentation: Precision Medicine Informed Immuno-Oncology as Mono- and Combination Therapy is Transforming Cancer Treatment	09:05 - 09:40
From Biomarkers to CDx: Strategies to accelerate CDx development and Commercialization
Conundrums of CDx Commercialization Philip Measor, Assistant Professor, Whitworth University	09:40 - 10:15
New molecular strategies for successful development of Immuno-Therapies Andrea Giuliani , Director, Business Development, Oncology and Precision Diagnostics, QIAGEN	10:15 - 10:50
Morning Refreshments and Poster Presentation \| One-to-One Networking Meetings	10:50 - 11:35
The use of reference materials to accelerate CDx development and commercialization Ronald Vos , Business Development Manager , SensID	11:35 - 12:10
From Multiplex discovery to IVD Diagnostics – A Biomarker journey Claire Huguet , Head, Biomarker Services , Randox Biosciences	12:10 - 12:45
The Diagnostic Toolkit for EBV-Associated Malignancies: Implications for Present and Future Yisrael Katz, Senior Medical Director , Viracta Therapeutics, Inc.	12:45 - 13:20
Lunch and Poster Presentation \| One-to-One Networking Meetings	13:20 - 14:20
BREAK OUT SESSION- Overcoming resistance to current cell therapy products John Rossi, Vice President, Head, Translational Medicine, , Syncopation Lifesciences	14:20 - 14:55
Chromosome 9p Loss Drives Immune Evasion and Checkpoint-Inhibitor Resistance in HPV— HNSC Scott Lippman , Director , Moores Cancer Center	14:55 - 15:30
Closing Remarks from the Chairman Paul Kassner, Senior Vice President, Quantitative & Computational Biology , RAPT Therapeutics	15:30 - 15:35
End of Conference	15:35 - 15:40